Zhuhai Tengbai Pharmaceutical

Zhuhai Tengbai Pharmaceutical is a biopharmaceutical company based in Zhuhai, China, specializing in the development of innovative treatments for metabolic disorders and chronic diseases. The company focuses on the research and development of multi-target incretin mimetics, with a lead candidate, TB001, acting as a dual agonist for the GLP-1 and GIP receptors. This program is currently being evaluated in clinical trials for the treatment of obesity and type 2 diabetes. In addition to its innovative pipeline, Zhuhai Tengbai is involved in the development of high-end generic drugs and complex formulations to address unmet medical needs. The company operates from the Jinwan District, leveraging local R&D infrastructure to advance its clinical and preclinical assets. Its strategic focus remains on metabolic health, aiming to provide more effective and accessible therapeutic options for patients globally.